Medicare officials have recently announced their plans to negotiate the prices of two popular drugs, Ozempic and Wegovy, used for diabetes and weight loss, respectively. These medications are among a list of 15 drugs that will undergo price negotiations this year as part of the Inflation Reduction Act, a program established by President Biden.
Ozempic and Wegovy are both derived from the same underlying medication but are prescribed for different conditions. Currently, Medicare covers Ozempic for diabetes but does not cover Wegovy for weight loss alone. However, the Biden administration has proposed a change to allow Medicare to cover Wegovy for certain obesity-related conditions, such as heart disease.
The inclusion of these high-profile drugs in the negotiation program is expected to raise public awareness of the initiative, which has struggled to gain traction. A recent poll conducted by the nonpartisan health policy research firm KFF showed that 45% of voters surveyed were unaware of the Inflation Reduction Act.
The decision to negotiate the prices of Ozempic and Wegovy comes at a critical time as the Trump administration is facing tough choices regarding how to provide coverage for these medications. The negotiations could potentially lead to lower prices for these drugs, making them more accessible to Medicare beneficiaries.
For more in-depth coverage and analysis of the biotech sector, subscribers can access exclusive articles like this one through STAT+. Subscribing to STAT+ will unlock a wealth of information on the latest developments in healthcare and pharmaceuticals. To learn more about subscription plans, visit the STAT+ website and stay informed on the latest news in the industry.
